EGFR and non-small cell lung carcinoma: The meta-analysis showed (Fig. 6) that immune checkpoint inhibitors versus chemotherapy had prolonged the NSCLC patients having EGFR wild-type for the OS (HR, 0.67; 95% CI, 0.60–0.76).